Results 1 to 10 of about 2,693 (199)

From Antipsychotic to Antitumor Agent: Cariprazine Suppresses Glioblastoma via D2/D3-ARRB2 Axis Modulation

Pharmaceuticals
Background: Glioblastoma (GBM) is among the malignant tumors with the lowest five-year survival rate. Current treatments offer limited efficacy and first-line options are scarce, highlighting the urgent need for novel drugs.
Haotian Zhang, Haowei Liu, Jiangpeng Xu, Xiaoling Li, Shasha Li, Xuemei Liu, Changhua Hu   +6 more
doaj   +2 more sources

Cariprazine as a strategy for augmentation of treatment of major depressive disorder: from pharmacological aspects to clinical practice

Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
Major depressive disorder remains the leading cause of disability worldwide, with up to 33% of patients failing to respond to antidepressant therapy.
A. V. Kidyaeva, R. F. Nasyrova
doaj   +1 more source

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine

Drug Design, Development and Therapy, 2019
Béla Kiss, Zsolt Némethy, Károly Fazekas, Dalma Kurkó, István Gyertyán, Katalin Sághy, István Laszlovszky, Bence Farkas, Norbert Kirschner, Etelka Bolf-Terjéki, Ottilia Balázs, Bal ...
Kiss B, Némethy Z, Fazekas K, Kurkó D, Gyertyán I, Sághy K, Laszlovszky I, Farkas B, Kirschner N, Bolf-Terjéki E, Balázs O, Lendvai B   +11 more
doaj  

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting

Frontiers in Psychiatry, 2023
Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were ...
Lluis Niell Galmes, Elmars Rancans
doaj   +1 more source

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies

Neuropsychiatric Disease and Treatment, 2021
Ágota Barabássy,1 Barbara Sebe,1 Károly Acsai,1 István Laszlovszky,1 Balázs Szatmári,1 Willie R Earley,2 György Németh1 1Medical Division, Gedeon Richter Plc, Budapest, Hungary; 2Clinical Development,
Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G   +6 more
doaj  

Cariprazine in the treatment of schizophrenia [PDF]

International Clinical Psychopharmacology, 2016
This 6-week, double-blind, placebo-controlled, proof-of-concept study evaluated the efficacy, safety, and tolerability of low-dose (1.5-4.5 mg/day) and high-dose (6-12 mg/day) cariprazine in patients with acute exacerbation of schizophrenia (NCT00404573).
Durgam, Suresh, Litman, Robert E., Papadakis, Kelly, Li, Dayong, Németh, György, Laszlovszky, István   +5 more
openaire   +2 more sources

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

BMC Psychiatry, 2021
Background While clinical trial evidence has firmly established the efficacy of several atypical antipsychotics (AAPs) for treating bipolar depression, no randomized controlled trials (RCT’s) comparing AAPs have been conducted. This Bayesian network meta-
Aditi Kadakia, Carole Dembek, Vincent Heller, Rajpal Singh, Jennifer Uyei, Katsuhiko Hagi, Tadashi Nosaka, Antony Loebel   +7 more
doaj   +1 more source

Effect of cariprazine on attention and quality of life in patients with predominant negative symptoms of schizophrenia: A post-hoc analysis

Schizophrenia Research: Cognition
Background: Cariprazine, a potent dopamine D3-preferring D3/D2 receptor partial agonist, has demonstrated benefits on negative symptoms among patients with schizophrenia.
Oloruntoba J. Oluboka, Andrea Bardell, Howard C. Margolese, Philip G. Tibbo, Lisa Buchy, Christine Di Cresce, Jun Yu, Roger S. McIntyre   +7 more
doaj   +1 more source

Efficacy and Tolerability of Cariprazine as Monotherapy for Acute Bipolar Depression: A Systematic Review and Meta-analysis

Journal of Psychiatry Spectrum
Background: Bipolar depression (BDep) presents a significant clinical challenge with limited treatment options. The second-generation antipsychotics are increasingly utilized as primary or adjunct treatments.
Poulami Laha, Rakshathi Basavaraju, Soumya Parameshwaran, Dinakaran Damodaran, Palash Kumar Malo, Binukumar Bhaskarapillai, Muralidharan Kesavan   +6 more
doaj   +1 more source

Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series

Neuropsychiatric Disease and Treatment, 2022
Juan D Duque-Yemail,1 Juan Carlos Avila2 1Psychiatry Resident, Department of Mental Health, Vall d’Hebron University Hospital, Barcelona, Spain; 2Psychiatrist, Mental Health Center, Badalona, SpainCorrespondence: Juan D Duque-Yemail, Vall d’Hebron ...
Duque-Yemail JD, Avila JC
doaj